To investigate the efficacy of CT measurement parameters combined with AI-assisted 3D planning for personalized femoral prosthesis selection in total hip arthroplasty (THA). A retrospective analysis was conducted on clinical data from 247 patients with unilateral hip or knee joint disorders treated at Renmin Hospital of Hubei University of Medicine between April 2021 and February 2024. All patients underwent preoperative full-pelvis and bilateral full-length femoral CT scans. The raw CT data were imported into Mimics 19.0 software to reconstruct a three-dimensional (3D) model of the healthy femur. Using 3-matic Research 11.0 software, the femoral head rotation center was located, and parameters including femoral head diameter (FHD), femoral neck length (FNL), femoral neck-shaft angle (FNSA), femoral offset (FO), femoral neck anteversion angle (FNAA), tip-apex distance (TAD), and tip-apex angle (TAA) were measured. AI-assisted THA 3D planning system AIJOINT V1.0.0.0 software was used for preoperative planning and design, enabling personalized selection of femoral prostheses with varying neck-shaft angles and surgical simulation. Groups were compared by gender, age, and parameters. ROC curves evaluated prediction efficacy. Females exhibited smaller FHD, FNL, FO, TAD, TAA but larger FNSA/FNAA vs males (P<0.05). Patients >65 years had higher FO, TAD, TAA (P<0.05). TAD-TAA correlation was strong (r=0.954), while FNSA negatively correlated with TAD/TAA (r=-0.773/-0.701). ROC analysis demonstrated high predictive accuracy: TAD (AUC=0.891, sensitivity=91.7%, specificity=87.6%) and TAA (AUC=0.882, sensitivity=100%, specificity=88.8%). CT parameters (TAA, TAD, FNSA, FO) are interrelated and effective predictors for femoral prosthesis selection. Integration with AI-assisted planning optimizes personalized THA, reducing biomechanical mismatch risks.

This narrative review outlines the current applications and considerations of artificial intelligence (AI) for diagnosis, management, and prognosis in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). Advances in AI, mainly in machine learning and deep learning, have significantly influenced medical research and clinical practice over the past decades by offering precisions in data understanding and treatment approaches. AI applications have enhanced risk prediction models, early diagnosis, and better management in RA. Predictive models have guided treatment decisions such as-response to methotrexate and biologics-while wearable devices and electronic health records (EHR) improve disease activity monitoring. In addition, AI applications are reported as promising for the early identification of extra-articular involvements, prediction, detection, and assessment of comorbidities. In axSpA, AI-driven models using imaging techniques such as sacroiliac radiography, magnetic resonance imaging, and computed tomography have increased diagnostic accuracy, especially for early inflammatory changes. Predictive algorithms help stratify and predict disease outcomes, while clinical decision support systems integrate clinical and imaging data for optimized management. For PsA, AI has also allowed for early detection among psoriasis patients using genetic markers, immune profiling, and EHR-based natural language processing systems. Overall, AI models may predict diagnosis, disease severity, treatment response, and comorbidities to improve care in patients with RA, axSpA, and PsA. As a rapidly developing and improving area, AI has the potential to change our current perspective of medical practice by offering better diagnostic evaluation and treatments and improved patient follow-up. Multimodal AI, focusing on collaboration, reliability, transparency, and patient-centered innovation, looks like the future of medical practice. However, data quality, model interpretability, and ethical considerations must be addressed to ensure reliable and equitable applications in clinical practice.

The use of artificial intelligence (AI) in medicine has shown promise to improve the quality of healthcare decisions. However, AI can be biased in a manner that produces unfair predictions for certain demographic subgroups. In MIMIC-CXR, a publicly available dataset of over 300,000 chest X-ray images, diagnostic AI has been shown to have a higher false negative rate for racial minorities. We evaluated the capacity of synthetic data augmentation, oversampling, and demographic-based corrections to enhance the fairness of AI predictions. We show that adjusting unfair predictions for demographic attributes, such as race, is ineffective at improving fairness or predictive performance. However, using oversampling and synthetic data augmentation to modify disease prevalence reduced such disparities by 74.7% and 10.6%, respectively. Moreover, such fairness gains were accomplished without reduction in performance (95% CI AUC: [0.816, 0.820] versus [0.810, 0.819] versus [0.817, 0.821] for baseline, oversampling, and augmentation, respectively).

Machine learning (ML) algorithms play a crucial role in the early and accurate diagnosis of Alzheimer's Disease (AD), which is essential for effective treatment planning. However, existing methods are not well-suited for identifying Mild Cognitive Impairment (MCI), a critical transitional stage between normal aging and AD. This inadequacy is primarily due to label imbalance and bias from different sensitve attributes in MCI classification. To overcome these challenges, we have designed an end-to-end fairness-aware approach for label-imbalanced classification, tailored specifically for neuroimaging data. This method, built on the recently developed FACIMS framework, integrates into STREAMLINE, an automated ML environment. We evaluated our approach against nine other ML algorithms and found that it achieves comparable balanced accuracy to other methods while prioritizing fairness in classifications with five different sensitive attributes. This analysis contributes to the development of equitable and reliable ML diagnostics for MCI detection.

Artificial intelligence (AI) shows promise in clinical tasks, yet its integration into workflows remains underexplored. This study proposes an AI-aided same-day diagnostic imaging workup to reduce recall rates following abnormal screening mammograms and alleviate patient anxiety while waiting for the diagnostic examinations. Using discrete simulation, we found minimal disruption to the workflow (a 4% reduction in daily patient volume or a 2% increase in operating time) under specific conditions: operation from 9 am to 12 pm with all radiologists managing all patient types (screenings, diagnostics, and biopsies). Costs specific to the AI-aided same-day diagnostic workup include AI software expenses and potential losses from unused pre-reserved slots for same-day diagnostic workups. These simulation findings can inform the implementation of an AI-aided same-day diagnostic workup, with future research focusing on its potential benefits, including improved patient satisfaction, reduced anxiety, lower recall rates, and shorter time to cancer diagnoses and treatment.